Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 54Stomach Neoplasms 42Carcinoma, Non-Small-Cell Lung 31Colorectal Neoplasms 21Esophageal Squamous Cell Carcinoma 15Nasopharyngeal Carcinoma 11Lung Neoplasms 11Rectal Neoplasms 10Esophageal Neoplasms 9Pancreatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 5Liver Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neoplasm Metastasis 4Carcinoma, Renal Cell 4Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Colonic Neoplasms 3Carcinoma 3Breast Neoplasms 3Turcot syndrome 2Thyroid Neoplasms 2Spinocerebellar Degenerations 2Sarcoma 2Nonsquamous Non-Small Cell Lung Cancer 2

Interventions

toripalimab 1tislelizumab 1spartalizumab 1sintilimab 1camrelizumab 1atezolizumab 1Taxes 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Locally Advanced or Metastatic Solid Tumors × sintilimab × Clear all
NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Chinese PLA General Hospital

Phase 1/2 Recruiting
40 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡